Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-000016-28
    Sponsor's Protocol Code Number:212483
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-08-30
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-000016-28
    A.3Full title of the trial
    A Phase IIb, randomized, double-blind, parallel-group study to assess the efficacy, safety, tolerability, and resistance profile of GSK3640254 in combination with dolutegravir compared to dolutegravir plus lamivudine in HIV-1 infected, treatment-naïve adults
    Studio di fase IIb, randomizzato, in doppio cieco, a gruppi paralleli volto a valutare l'efficacia, la sicurezza, la tollerabilità e il profilo di resistenza di GSK3640254 in combinazione con dolutegravir rispetto a dolutegravir più lamivudina in adulti con infezione da HIV-1, naïve al trattamento
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase IIb Clinical Trial of GSK3640254 + Dolutegravir (DTG) in HIV-1 Infected Treatment-Naive Adults
    Studio clinico di fase IIb su GSK3640254 + dolutegravir (DTG) in adulti con infezione da HIV-1, naïve al trattamento
    A.3.2Name or abbreviated title of the trial where available
    DYNAMIC
    DYNAMIC
    A.4.1Sponsor's protocol code number212483
    A.5.4Other Identifiers
    Name:IND NumberNumber:139838
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorVIIV HEALTHCARE UK LIMITED
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportViiV Healthcare UK (No. 4) Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGlaxoSmithKline Research & Development Ltd.
    B.5.2Functional name of contact pointGSK Clinical Support HelpDesk
    B.5.3 Address:
    B.5.3.1Street Address980 Great West Road
    B.5.3.2Town/ cityBrentford, Middlesex
    B.5.3.3Post codeTW8 9GS
    B.5.3.4CountryUnited Kingdom
    B.5.6E-mailGSKClinicalSupportHD@gsk.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name TIVICAY - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderVIIV HEALTHCARE UK LTD
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTivicay 50 mg film-coated tablets
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDOLUTEGRAVIR
    D.3.9.1CAS number 1051375-19-9
    D.3.9.2Current sponsor code-
    D.3.9.3Other descriptive nameDOLUTEGRAVIR
    D.3.9.4EV Substance CodeSUB35122
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Epivir
    D.2.1.1.2Name of the Marketing Authorisation holderViiV Healthcare
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEpivir 300 mg film-coated tablets
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLAMIVUDINA
    D.3.9.1CAS number 134678-17-4
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameLamivudine
    D.3.9.4EV Substance CodeSUB08392MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGSK3640254
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 1818867-24-1
    D.3.9.2Current sponsor codeGSK3640254
    D.3.9.3Other descriptive nameGSK3640254D where D denotes the methanesulfonate salt
    D.3.9.4EV Substance CodeSUB218087
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Epivir
    D.2.1.1.2Name of the Marketing Authorisation holderViiV Healthcare
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOver-encapsulated Epivir® (Lamivudine) Tablets
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLAMIVUDINA
    D.3.9.1CAS number 134678-17-4
    D.3.9.2Current sponsor code-
    D.3.9.3Other descriptive nameLamivudine
    D.3.9.4EV Substance CodeSUB08392MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGSK3640254
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 1818867-24-1
    D.3.9.2Current sponsor codeGSK3640254
    D.3.9.3Other descriptive nameGSK3640254D where D denotes the methanesulfonate salt
    D.3.9.4EV Substance CodeSUB218087
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name EPIVIR - 300 MG 1 FLACONE 30 COMPRESSE RIVESTITE CON FILM USO ORALE
    D.2.1.1.2Name of the Marketing Authorisation holderVIIV HEALTHCARE UK LTD
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEpivir 300 mg film-coated tablets
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLAMIVUDINA
    D.3.9.1CAS number 134678-17-4
    D.3.9.2Current sponsor code-
    D.3.9.3Other descriptive nameLamivudine
    D.3.9.4EV Substance CodeSUB08392MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Human Immunodeficiency Virus Type-1 (HIV-1)
    Virus dell'immunodeficienza umana di tipo 1 (HIV-1)
    E.1.1.1Medical condition in easily understood language
    HIV infection
    Infezione da HIV
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10068341
    E.1.2Term HIV-1 infection
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate antiviral efficacy of GSK3640254 + DTG, relative to DTG + 3TC at Week 24 in HIV-1 infected, ART-naïve participants
    Valutare l'efficacia antivirale di GSK3640254 + DTG, rispetto a DTG + 3TC alla Settimana 24 in partecipanti con infezione da HIV-1 e naïve alla ART
    E.2.2Secondary objectives of the trial
    • To evaluate the antiviral activity of GSK3640254 + DTG relative to DTG + 3TC at Week 48;
    • To evaluate safety and tolerability of GSK3640254 when given in combination with DTG, relative to DTG + 3TC;
    • To assess the development of viral resistance to GSK3640254 and other on-study ART in participants experiencing virologic failure through Week 48;
    • To assess the steady-state exposure of GSK3640254 when given in combination with DTG.
    • Valutare l'attività antivirale di GSK3640254 + DTG rispetto a DTG + 3TC alla settimana 48;
    • Valutare la sicurezza e la tollerabilità di GSK3640254 quando somministrato in combinazione con DTG, rispetto a DTG + 3TC;
    • Valutare lo sviluppo della resistenza virale a GSK3640254 e ad altri ART in studio nei partecipanti che hanno manifestato fallimento virologico fino alla settimana 48;
    • Per valutare l'esposizione allo stato stazionario di GSK3640254 quando somministrato in combinazione con DTG.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Age:
    1. Participants must be 18 years of age inclusive, at the time of signing the informed consent.
    Type of Participant and Disease Characteristics:
    2. Treatment-naïve, defined as no ARVs (in combination or monotherapy) received after a known diagnosis of HIV-1 infection;
    NOTE: Use of PrEP (prior to known HIV-1 infection) is allowed and still meets inclusion. PrEP is used by individuals who are not infected with HIV-1 but who are at high risk for acquiring the virus. PrEP alone is not sufficient to treat HIV and the use of PrEP is stopped if/when a diagnosis of HIV is made.
    3. Documented HIV infection and Screening plasma HIV-1 RNA =1000 c/mL;
    4. Screening CD4+ T-cell count =300 cells/mm3;
    Weight:
    5. Body weight =50.0 kg (110 lbs.) for men and =45.0 kg (99 lbs) for women and body mass index (BMI) > 18.5 kg/m2. Calculations will utilize sex assigned at birth;
    Sex:
    Sex and Contraceptive/Barrier Requirements:
    6. Male and female
    a. Participants who are male at birth: There are no contraceptive requirements for participants who are male at birth
    b. Participants who are female at birth:
    Contraceptive use by participants who are female at birth should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    • A participant who is female at birth is eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:
    o Is not a participant of childbearing potential (PONCBP) as defined in Section 10.4. OR
    o Is a POCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, as described in Section 10.4 during the study intervention period and until after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.
    o If a hormonal method is selected, the participant is required to be clinically stable on it for at least one month prior to starting treatment in the study.
    • A POCBP must have a negative highly sensitive serum pregnancy test at Screening and a negative urine pregnancy test at Day 1 before starting study intervention .
    o If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
    • Additional requirements for pregnancy testing during and after study intervention are located in Section 8.2.5 Pregnancy Testing.
    • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a participant with an early undetected pregnancy Informed Consent:
    7. Capable of giving signed informed consent as described in Section 10.1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
    Other:
    8. For participants enrolled in France: a participant will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
    Età:
    1. I partecipanti devono avere almeno 18 anni di età, al momento della firma del consenso informato.
    Tipo di partecipante e caratteristiche della malattia:
    2. Naïve al trattamento, definito come nessun ARV (in combinazione o in monoterapia) ricevuto dopo una diagnosi nota di infezione da HIV-1;
    NOTA: l'uso della PrEP (prima dell'infezione nota da HIV-1) è consentito e continua a soddisfare l'inclusione. La PrEP viene utilizzata da individui che non sono infetti da HIV-1 ma che sono ad alto rischio di contrarre il virus. La PrEP da sola non è sufficiente per trattare l'HIV e l'uso della PrEP viene interrotto se / quando viene fatta una diagnosi di HIV.
    3. Infezione da HIV documentata e screening plasmatico di HIV-1 RNA =1000 c / mL;
    4. Screening della conta dei linfociti T CD4 + =300 cellule / mm3;
    Peso:
    5. Peso corporeo =50,0 kg (110 libbre) per gli uomini e =45,0 kg (99 libbre) per le donne e indice di massa corporea (BMI)> 18,5 kg / m2. I calcoli utilizzeranno il sesso assegnato alla nascita;
    Sesso:
    Requisiti relativi a sesso e contraccettivo / barriera:
    6. Maschio e femmina
    un. Partecipanti maschi alla nascita: non ci sono requisiti contraccettivi per i partecipanti maschi alla nascita
    b. Partecipanti femmine alla nascita:
    L'uso di contraccettivi da parte di partecipanti di sesso femminile alla nascita deve essere coerente con le normative locali relative ai metodi di contraccezione per coloro che partecipano a studi clinici.
    • Una partecipante che è una donna alla nascita può partecipare se non è incinta o se allatta al seno e si applica una delle seguenti condizioni:
    o Non è un partecipante in età fertile (PONCBP) come definito nella Sezione 10.4. O
    o È un POCBP e utilizza un metodo contraccettivo altamente efficace (con un tasso di fallimento <1% all'anno), con bassa dipendenza dell'utente, come descritto nella Sezione 10.4 durante il periodo di intervento dello studio e fino a dopo l'ultima dose dell'intervento in studio . Lo sperimentatore deve valutare il potenziale di fallimento del metodo contraccettivo (ad es. Non conformità, iniziato di recente) in relazione alla prima dose dell'intervento in studio.
    o Se viene selezionato un metodo ormonale, il partecipante deve essere clinicamente stabile su di esso per almeno un mese prima di iniziare il trattamento nello studio.
    • Un POCBP deve avere un test di gravidanza su siero altamente sensibile negativo allo Screening e un test di gravidanza sulle urine negativo al Giorno 1 prima di iniziare l'intervento dello studio.
    o Se un test delle urine non può essere confermato come negativo (ad esempio, un risultato ambiguo), è necessario un test di gravidanza sul siero. In tali casi, la partecipante deve essere esclusa dalla partecipazione se il risultato della gravidanza sierica è positivo.
    • Ulteriori requisiti per i test di gravidanza durante e dopo l'intervento in studio si trovano nella Sezione 8.2.5 Test di gravidanza.
    • Lo sperimentatore è responsabile della revisione della storia medica, della storia mestruale e dell'attività sessuale recente per ridurre il rischio di inclusione di una partecipante con una gravidanza precoce non rilevata Consenso informato:
    7. Capace di dare il consenso informato firmato come descritto nella Sezione 10.1 che include la conformità con i requisiti e le restrizioni elencati nel modulo di consenso informato (ICF) e in questo protocollo.
    Altro:
    8. Per i partecipanti iscritti in Francia: un partecipante potrà essere incluso in questo studio solo se affiliato o beneficiario di una categoria di sicurezza sociale.
    Ulteriori informazioni su questo testo di originePer avere ulteriori informazioni sulla traduzione è necessario il testo di origine
    E.4Principal exclusion criteria
    1. Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3 disease [CDC, 2014], except cutaneous Kaposi's sarcoma not requiring systemic therapy;
    2. Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia;
    3. Presence of primary HIV infection, evidenced by acute retroviral syndrome (e.g., fever, malaise, fatigue, etc) and/or evidence of recent (within 3 months) documented viremia without antibody production and/or evidence of recent (within 3 months) documented seroconversion;
    4. Known history of liver cirrhosis with or without viral hepatitis coinfection;
    5. Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment)
    6. History of ongoing or clinically relevant hepatitis within the previous 6 months;
    7. History of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation;
    8. Any history of significant underlying psychiatric disorder, in the opinion of the Investigator or Medical Monitor, including but not limited to schizophrenia, bipolar disorder with or without psychotic symptoms, other psychotic disorders, or schizotypal (personality) disorder; or a clinical assessment of suicidality based on the responses on the CSSRS.
    9. Any history of major depressive disorder with or without suicidal features, or anxiety disorders, that required medical intervention (pharmacologic or not) such as hospitalization or other inpatient treatment and/or chronic (>6 months) outpatient treatment;
    10. Any pre-existing physical or other psychiatric condition (including alcohol or drug abuse), which, in the opinion of the Investigator or Medical Monitor (with or without psychiatric evaluation), could interfere with the participant's ability to comply with the dosing schedule and protocol evaluations or which might compromise the safety of the participant;
    11. A pre-existing condition, in the opinion of the Investigator or Medical Monitor, that could interfere with normal gastrointestinal anatomy or motility (e.g., gastroesophageal reflux disease [GERD], gastric ulcers, gastritis, inflammatory bowel disease), hepatic and/or renal function, or with the absorption, metabolism, and/or excretion of the study interventions or render the participant unable to take oral study treatment;
    12. Myocardial infarction, acute coronary syndrome, unstable angina, stroke, transient ischemic attack, or intermittent claudication in the past 3 months;
    13. Familial or personal history of long QT syndrome or sudden cardiac death;
    14. Medical history, current or historical, of significant cardiac arrhythmias or ECG findings which, in the opinion of the Investigator or Medical Monitor, will interfere with the safety of the participant;
    15. Active treatment for a viral infection other than HIV-1, such as Hepatitis B, with an agent that is active against HIV-1 (were known to be infected with HIV-1 after treatment for Hepatitis B was completed);
    16. Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening;
    17. Treatment with any of the following agents within 28 days of Screening: radiation therapy, cytotoxic chemotherapeutic agents, any systemic immune suppressant;
    18. Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication;
    1. Qualsiasi evidenza di una malattia allo stadio 3 dei Centri per il controllo e la prevenzione (CDC) attiva [CDC, 2014], ad eccezione del sarcoma cutaneo di Kaposi che non richiede terapia sistemica;
    2. Malignità in atto diversa dal sarcoma cutaneo di Kaposi, carcinoma basocellulare o carcinoma squamocellulare cutaneo resecato, non invasivo, o neoplasia intraepiteliale cervicale, anale o peniena;
    3. Presenza di infezione primaria da HIV, evidenziata da sindrome retrovirale acuta (p. Es., Febbre, malessere, affaticamento, ecc.) E / o evidenza di viremia documentata recente (entro 3 mesi) senza produzione di anticorpi e / o evidenza di recente (entro 3 mesi) ) sieroconversione documentata;
    4. Anamnesi nota di cirrosi epatica con o senza coinfezione da epatite virale;
    5. Malattia epatica instabile (come definita da uno dei seguenti: presenza di ascite, encefalopatia, coagulopatia, ipoalbuminemia, varici esofagee o gastriche o ittero persistente o cirrosi), anomalie biliari note (ad eccezione della sindrome di Gilbert o dei calcoli biliari asintomatici o malattia epatica cronica altrimenti stabile secondo la valutazione dello sperimentatore)
    6. Storia di epatite in corso o clinicamente rilevante nei 6 mesi precedenti;
    7. Storia di allergia a farmaci o altre allergie che, a giudizio dello sperimentatore o del Medical Monitor, controindica la loro partecipazione;
    8. Qualsiasi storia di disturbo psichiatrico sottostante significativo, secondo l'opinione dello Sperimentatore o del Monitor medico, inclusi ma non limitati a schizofrenia, disturbo bipolare con o senza sintomi psicotici, altri disturbi psicotici o disturbo schizotipico (di personalità); o una valutazione clinica del suicidio basata sulle risposte del CSSRS.
    9. Qualsiasi storia di disturbo depressivo maggiore con o senza caratteristiche suicide, o disturbi d'ansia, che ha richiesto un intervento medico (farmacologico o meno) come ricovero in ospedale o altro trattamento ospedaliero e / o trattamento ambulatoriale cronico (> 6 mesi);
    10. Qualsiasi condizione fisica o psichiatrica preesistente (incluso l'abuso di alcol o droghe) che, a parere dello sperimentatore o del monitor medico (con o senza valutazione psichiatrica), potrebbe interferire con la capacità del partecipante di rispettare il programma di dosaggio e valutazioni del protocollo o che potrebbero compromettere la sicurezza del partecipante;
    11. Una condizione preesistente, secondo il parere dello sperimentatore o del monitor medico, che potrebbe interferire con la normale anatomia o motilità gastrointestinale (ad esempio, malattia da reflusso gastroesofageo [GERD], ulcere gastriche, gastrite, malattia infiammatoria intestinale), epatica e / o la funzione renale, o con l'assorbimento, il metabolismo e / o l'escrezione degli interventi di studio o rendono il partecipante incapace di prendere il trattamento di studio orale;
    12. Infarto miocardico, sindrome coronarica acuta, angina instabile, ictus, attacco ischemico transitorio o claudicatio intermittente negli ultimi 3 mesi;
    13. Storia familiare o personale di sindrome del QT lungo o morte cardiaca improvvisa;
    14. Anamnesi, attuale o storica, di aritmie cardiache significative o reperti ECG che, a parere dello sperimentatore o del monitor medico, interferiranno con la sicurezza del partecipante;
    15. Trattamento attivo per un'infezione virale diversa dall'HIV-1, come l'epatite B, con un agente attivo contro l'HIV-1 (si sapeva che era infetto da HIV-1 dopo il completamento del trattamento per l'epatite B);
    16. Trattamento con un vaccino immunoterapico contro l'HIV-1 entro 90 giorni dallo Screening;
    17. Trattamento con uno qualsiasi dei seguenti agenti entro 28 giorni dallo screening: radioterapia, agenti chemioterapici citotossici, qualsiasi immunosoppressore sistemico;
    18. Partecipanti che ricevono farmaci proibiti dal protocollo e che non vogliono o non sono in grado di passare a un farmaco alternativo;
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of participants with plasma HIV-1 RNA <50 c/mL at Week 24 using the FDA snapshot algorithm
    Proporzione di partecipanti con HIV-1 RNA plasmatico <50 c / mL alla settimana 24 utilizzando l'algoritmo snapshot della FDA
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 24
    24 settimane
    E.5.2Secondary end point(s)
    • Proportion of participants with plasma HIV-1 RNA <50 c/mL at Week
    48 using the FDA snapshot algorithm;
    • Absolute values and changes from baseline in HIV-1 RNA through
    Weeks 24 and 48;
    • Absolute values and changes from baseline in CD4+ T-cell counts
    through Weeks 24 and 48;
    • Frequency of SAEs, Deaths and AEs leading to Discontinuation through
    Weeks 24 and 48;
    • AEs of special interest (AESIs) through Weeks 24 and 48;
    • Changes in genotypic and/or phenotypic profiles of virus compared to
    baseline;
    • The steady-state plasma PK parameters of GSK3640254 will be
    assessed based on Sparse PK sampling through Week 48
    • Proporzione di partecipanti con HIV-1 RNA plasmatico <50 c / mL alla settimana
    48 utilizzando l'algoritmo di snapshot della FDA;
    • Valori assoluti e variazioni dal basale in HIV-1 RNA fino a
    Settimane 24 e 48;
    • Valori assoluti e variazioni rispetto al basale nella conta dei linfociti T CD4 +
    fino alle settimane 24 e 48;
    • Frequenza di eventi avversi gravi, decessi e eventi avversi che hanno portato all'interruzione tramite
    Settimane 24 e 48;
    • Eventi avversi di interesse speciale (AESI) fino alle settimane 24 e 48;
    • Cambiamenti nei profili genotipici e / o fenotipici del virus rispetto a
    linea di base;
    • I parametri PK plasmatici allo stato stazionario di GSK3640254 saranno
    valutato sulla base del campionamento PK sparse fino alla settimana 48
    E.5.2.1Timepoint(s) of evaluation of this end point
    Please refer to the time period specified in E.5.2 Secondary end point section.
    Fare riferimento al periodo di tempo specificato nella sezione E.5.2 Endpoint secondario.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability, Resistance profile, Viral Genotyping and Phenotyping
    Tollerabilità, profilo di resistenza, genotipizzazione virale e fenotipizzazione
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA31
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Puerto Rico
    Russian Federation
    South Africa
    United States
    France
    Germany
    Italy
    Poland
    Portugal
    Spain
    Argentina
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the date of the last visit of the last participant in the study.
    A participant is considered to have completed the study if the participant has completed all phases of the study including the last visit.
    La fine dello studio è definita come la data dell'ultima visita dell'ultimo partecipante allo studio.
    Si considera che un partecipante abbia completato lo studio se ha completato tutte le fasi dello studio inclusa l'ultima visita.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 90
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 30
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state16
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 55
    F.4.2.2In the whole clinical trial 120
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    To provide continued access to an unapproved investigational drug to participants deriving additional therapeutic benefit not expected from locally available standard of care, participants that received GSK3640254 + DTG and who have successfully completed 52 weeks of treatment will be given the opportunity to continue to receive GSK3640254 + DTG as per conditions specified in the protocol until GSK3640254 + DTG is commercially available.
    Fornire accesso continuo a un farmaco sperimentale non approvato ai partecipanti che traggono benefici terapeutici aggiuntivi non attesi dallo standard di cura disponibile a livello locale, i partecipanti che hanno ricevuto GSK3640254 + DTG e che hanno completato con successo 52 settimane di trattamento avranno l'opportunità di continuare a ricevere GSK3640254 + DTG secondo le condizioni specificate nel protocollo fino a quando GSK3640254 + DTG non sarà disponibile in commercio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-08-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-09-08
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2023-02-01
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:58:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA